

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

John Hiscott et al.

Serial No.

09/647,965

Filed

: October 6, 2000

For

HIGHLY ACTIVE FORMS OF INTERFERON

REGULATORY FACTOR PROTEINS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents,

on June 8, 2001

Rochelle K. Seide

Washington, D.C. 20231

Assistant Commissioner for Patents Box PCT Washington, DC 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97 (b), applicants bring to the attention of the Examiner the document listed on the attached PTO Form 1449, a copy of which is attached. This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

NY02:328839.1 - 1 -

Applicants respectfully request that the Examiner consider the listed document and

indicate that it was considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art

exists and does not constitute an admission that the listed document is material or constitutes

"prior art." If the Examiner applies the document as prior art against any claim in the

application and applicants determine that the cited document does not constitute "prior art"

under United States law, applicants reserve the right to present to the office the relevant facts

and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the

patentability of the disclosed invention over the listed document, should the document be

applied against the claims of the present application.

The Commissioner is hereby authorized to charge the payment of any additional fees

required in connection with this communication to our Deposit Account No. 02-4377.

Respectfully submitted,

Rochelle K. Seide

Patent Office Reg. No. 32,300

Attorney for Applicants

(212) 408-2574

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office

Examiner

Atty. Docket No. Serial No. A33606 PCT USA-071235.0111 09/647,965

Applicant

John Hiscott et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date
October 6, 2000

Group

	(Use seprecal sheets if necessary)														
			1 4												
	-	JUN 1	7 2001	<u>*</u>			Ū.	S. PATENT I	DOCUMEN	NTS				*	
*Exam. Init.	1	· ·	2001 Branent No.				Date	Date	Name		Class	Subclass	Filing Date ifAppropriate		
		- TA	DEN					*							
															
						ļ									
				<u> </u>	<u> </u>										
							FC	DREIGN PATE	NT DOCUME	ENT					
		Document No.						Date		Country	Class	SubClass	Translator Yes No		
·		<u> </u>												i .	
														<u> </u>	
														ļ <u> </u>	
· · · · · ·	-			ОТН	ER D	OCU.	MENT	S (including Aut	thor, Title Da	te, Pertiner	t Pages, Etc.)				
		Cohen, Lucie and Hiscott, John, "Characterization of TH3, an Induction-Specific Protein Interacting with the Interferon β Promoter." 1992. 589-599.													
									_						

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.